SEC Form 4 · accession 0001209191-17-037923

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — EVP\Chief Commercial Officer

Period of report

Jun 1, 2017

Accepted (ET)

Jun 5, 2017 · 6:06 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Jun 1, 2017	M	13,594	$53.74	A	145,061	D
Common Stock^F2,F3	Jun 1, 2017	S	13,594	$124.00	D	131,467	D
Common Stock	Jun 2, 2017	M	25,500	$77.31	A	156,967	D
Common Stock	Jun 2, 2017	M	31,875	$83.36	A	188,842	D
Common Stock^F3,F4	Jun 2, 2017	S	57,375	$129.02	D	131,467	D
Common Stock	holding	—	—		—	140	I	401(k)

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F5	$53.74	Jun 1, 2017	M	13,594	D	—	Sep 3, 2022	Common Stock	13,594	0	D
Stock Option (Right to Buy)^F6	$77.31	Jun 2, 2017	M	25,500	D	—	Feb 4, 2024	Common Stock	25,500	12,750	D
Stock Option (Right to Buy)^F7	$83.36	Jun 2, 2017	M	31,875	D	—	Jul 29, 2023	Common Stock	31,875	2,125	D

F1Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.
F2Open market sales reported on this line occurred at a weighted average price of $124.00 (range $124.00 to $124.04).
F3Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F4Open market sales reported on this line occurred at a weighted average price of $129.02 (range $129.00 to $129.16).
F5Fully vested.
F6The option vests in 16 quarterly installments from 02/05/2014.
F7The option vests in 16 quarterly installments from 07/30/2013.